Favorable clinical response and drug retention of anti-IL-6 receptor inhibitor in rheumatoid arthritis with high CRP levels: the ANSWER cohort study-Reference-Cited by-同舟云学术

Favorable clinical response and drug retention of anti-IL-6 receptor inhibitor in rheumatoid arthritis with high CRP levels: the ANSWER cohort study

Published:2021-09-13 Issue: Volume: Page:1-10
ISSN:0300-9742
Container-title:Scandinavian Journal of Rheumatology
language:en
Short-container-title:Scandinavian Journal of Rheumatology

Author:

Nakayama Y¹,Hashimoto M²³,Watanabe R²³,Murakami K¹,Murata K²⁴,Tanaka M²,Ito H²⁴,Yamamoto W²⁵,Ebina K⁶,Hata K⁷,Hiramatsu Y⁷,Katayama M⁸,Son Y⁹,Amuro H⁹,Akashi K¹⁰,Onishi A¹⁰,Hara R¹¹,Yamamoto K¹²,Ohmura K¹,Matsuda S⁴,Morinobu A¹

Affiliation:

1. Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan

2. Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan

3. Department of Clinical Immunology, Graduate School of Medicine, Osaka City University, Osaka, Japan

4. Department of Orthopaedic Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan

5. Department of Health Information Management, Kurashiki Sweet Hospital, Okayama, Japan

6. Department of Musculoskeletal Regenerative Medicine, Osaka University Graduate School of Medicine, Osaka, Japan

7. Department of Internal Medicine IV, Division of Rheumatology, Osaka Medical College, Osaka, Japan

8. Department of Rheumatology, Osaka Red Cross Hospital, Osaka, Japan

9. First Department of Internal Medicine, Kansai Medical University, Osaka, Japan

10. Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Hyogo, Japan

11. The Center for Rheumatic Diseases, Department of Orthopaedic Surgery, Nara Medical University, Nara, Japan

12. Department of Medical Informatics, Wakayama Medical University, Wakayama, Japan

Publisher

Informa UK Limited

Subject

Immunology,General Medicine,Immunology and Allergy,Rheumatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/03009742.2021.1947005

Reference35 articles.

1. Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges

2. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update

3. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

4. Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial

5. Predictive factors for induction of remission in patients with active rheumatoid arthritis treated with tocilizumab in clinical practice

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug retention of biologics and Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study;RMD Open;2023-08

2. Comparative effectiveness of TNF inhibitor vs IL-6 receptor inhibitor as monotherapy or combination therapy with methotrexate in biologic-experienced patients with rheumatoid arthritis: An analysis from the CorEvitas RA Registry;Clinical Rheumatology;2023-04-15

3. Euphorbium total triterpenes improve Freund's complete adjuvant-induced arthritis through PI3K/AKT/Bax and NF-κB/NLRP3 signaling pathways;Journal of Ethnopharmacology;2023-04

4. Baseline erythrocyte sedimentation rate level predicts long-term inhibition of radiographic progression by tocilizumab: the KURAMA cohort;Immunological Medicine;2023-01-23

5. Add-on effectiveness of methotrexate or iguratimod in patients with rheumatoid arthritis exhibiting an inadequate response to Janus kinase inhibitors: The ANSWER cohort study;Modern Rheumatology;2022-08-13